Literature DB >> 1698179

Protective activities in mice of monoclonal antibodies against pertussis toxin.

H Sato1, Y Sato.   

Abstract

Pertussis toxin (PT) protein, which is the most important protective antigen of Bordetella pertussis, has a hexameric structure composed of five subunits, designated S1 through S5. Immunoprotective activity of 20 different mouse monoclonal antibodies (MAbs) against pertussis toxin, 10 anti-S1, 1 anti-S2, 2 anti-S3, 4 anti-S23, and 3 anti-S4 antibodies, were investigated by aerosol and intracerebral challenges with virulent B. pertussis organisms in mice. Four anti-S1, named 1B7, 1D7, 3F11, and 10D6, and three anti-S23 antibodies, named 11E6, 10B5, and 10C9, showed the highest, and almost complete, protectivity against the aerosol challenge. Mouse protectivity against the intracerebral challenge was significant for these four anti-S1 MAbs but not for any of the three anti-S23 MAbs. Four anti-S1 and two anti-S4 MAbs did not protect the mice against either challenge. The other seven MAbs also showed dose-dependent moderate but significant protection against the aerosol challenge. In the aerosol challenge system, bacterial numbers and amounts of PT detected in the lung and the number of peripheral leukocytes were lower in the mice given the protective MAbs. All mice surviving 5 weeks after the infection produced high titers of antibodies against PT, filamentous hemagglutinin (FHA), and agglutinogens from the challenge organisms. A combination of the protective MAbs 1B7 and 11E6 strongly suppressed the disease and mortality of the mice at smaller amounts than with the anti-PT polyclonal antibody. Although combinations of one of the protective MAb and anti-FHA or anti-agglutinogen 2 also showed extremely high mouse protection without development of symptoms of the disease, antibody titers of the survivors against PT, FHA, and agglutinogens were significantly low. The foregoing results suggest that some important protective epitopes should be in S1 and S2 and/or S3, although there are both differences and similarities in the protective roles between anti-S1 and anti-S23 antibodies and also in the pathogenic mechanisms between aerosol and intracerebral infections. Furthermore, it was suggested that although not only FHA and agglutinogen 2 but also PT have roles as attachment factors, the processes of infection and protection are different between mice immunized with antibody against FHA or agglutinogen 2 and that against PT because the latter mice are also able to neutralize toxicity of PT diffused into the mice.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1698179      PMCID: PMC313662          DOI: 10.1128/iai.58.10.3369-3374.1990

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  19 in total

1.  Secondary analyses of the efficacy of two acellular pertussis vaccines evaluated in a Swedish phase III trial.

Authors:  J Storsaeter; H Hallander; C P Farrington; P Olin; R Möllby; E Miller
Journal:  Vaccine       Date:  1990-10       Impact factor: 3.641

2.  Characterization of two adhesins of Bordetella pertussis for human ciliated respiratory-epithelial cells.

Authors:  E Tuomanen; A Weiss
Journal:  J Infect Dis       Date:  1985-07       Impact factor: 5.226

3.  Role of antibody to leukocytosis-promoting factor hemagglutinin and to filamentous hemagglutinin in immunity to pertussis.

Authors:  Y Sato; K Izumiya; H Sato; J L Cowell; C R Manclark
Journal:  Infect Immun       Date:  1981-03       Impact factor: 3.441

4.  Synergistic effect of Bordetella pertussis lymphocytosis-promoting factor on protective activities of isolated Bordetella antigens in mice.

Authors:  A Robinson; L I Irons
Journal:  Infect Immun       Date:  1983-05       Impact factor: 3.441

5.  Bordetella pertussis filamentous hemagglutinin: evaluation as a protective antigen and colonization factor in a mouse respiratory infection model.

Authors:  A Kimura; K T Mountzouros; D A Relman; S Falkow; J L Cowell
Journal:  Infect Immun       Date:  1990-01       Impact factor: 3.441

6.  Monoclonal antibody against pertussis toxin: effect on toxin activity and pertussis infections.

Authors:  H Sato; A Ito; J Chiba; Y Sato
Journal:  Infect Immun       Date:  1984-11       Impact factor: 3.441

7.  Bordetella pertussis infection in mice: correlation of specific antibodies against two antigens, pertussis toxin, and filamentous hemagglutinin with mouse protectivity in an intracerebral or aerosol challenge system.

Authors:  H Sato; Y Sato
Journal:  Infect Immun       Date:  1984-11       Impact factor: 3.441

8.  Aerosol infection of mice with Bordetella pertussis.

Authors:  Y Sato; K Izumiya; H Sato; J L Cowell; C R Manclark
Journal:  Infect Immun       Date:  1980-07       Impact factor: 3.441

9.  Heptakis(2,6-O-dimethyl)beta-cyclodextrin: a novel growth stimulant for Bordetella pertussis phase I.

Authors:  A Imaizumi; Y Suzuki; S Ono; H Sato; Y Sato
Journal:  J Clin Microbiol       Date:  1983-05       Impact factor: 5.948

10.  Mouse-protecting and histamine-sensitizing activities of pertussigen and fimbrial hemagglutinin from Bordetella pertussis.

Authors:  J J Munoz; H Arai; R L Cole
Journal:  Infect Immun       Date:  1981-04       Impact factor: 3.441

View more
  37 in total

1.  Use of pertussis toxin encoded by ptx genes from Bordetella bronchiseptica to model the effects of antigenic drift of pertussis toxin on antibody neutralization.

Authors:  S Z Hausman; D L Burns
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

2.  Temporal expression of pertussis toxin and Ptl secretion proteins by Bordetella pertussis.

Authors:  Amy A Rambow-Larsen; Alison A Weiss
Journal:  J Bacteriol       Date:  2004-01       Impact factor: 3.490

3.  Expression of a C terminally truncated form of pertussis toxin S1 subunit effectively induces protection against pertussis toxin following DNA-based immunization.

Authors:  Kazunari Kamachi; Yoshichika Arakawa
Journal:  Infect Immun       Date:  2004-07       Impact factor: 3.441

4.  Generation of human monoclonal antibodies that confer protection against pertussis toxin.

Authors:  M Zaccolo; S Roggero; D Armellini; L Pegoraro; R Rappuoli; F Malavasi
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

5.  Antibody nanoparticle dispersions formed with mixtures of crowding molecules retain activity and in vivo bioavailability.

Authors:  Maria A Miller; Tarik A Khan; Kevin J Kaczorowski; Brian K Wilson; Aileen K Dinin; Ameya U Borwankar; Miguel A Rodrigues; Thomas M Truskett; Keith P Johnston; Jennifer A Maynard
Journal:  J Pharm Sci       Date:  2012-07-06       Impact factor: 3.534

6.  Immunoglobulin A-mediated protection against Bordetella pertussis infection.

Authors:  S M Hellwig; A B van Spriel; J F Schellekens; F R Mooi; J G van de Winkel
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

7.  Characterization of murine monoclonal antibodies that recognize defined epitopes of pertussis toxin and neutralize its toxic effect on Chinese hamster ovary cells.

Authors:  M J Walker; J Wehland; K N Timmis; B Raupach; M A Schmidt
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

8.  Fusion expression and immunogenicity of Bordetella pertussis PTS1-FHA protein: implications for the vaccine development.

Authors:  Zhang Jinyong; Zhang Xiaoli; Zhang Weijun; Guo Ying; Guo Gang; Mao Xuhu; Zou Quanming
Journal:  Mol Biol Rep       Date:  2010-09-28       Impact factor: 2.316

9.  Comparison of pertussis toxin (PT)-neutralizing activities and mouse-protective activities of anti-PT mouse monoclonal antibodies.

Authors:  H Sato; Y Sato; I Ohishi
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

Review 10.  Progress towards recombinant anti-infective antibodies.

Authors:  Jennifer C Pai; Jamie N Sutherland; Jennifer A Maynard
Journal:  Recent Pat Antiinfect Drug Discov       Date:  2009-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.